Key Takeaways Diagnostics core revenues rose 2% year over year in Q2 2025.Beckman Coulter Diagnostics grew at high single digits outside China.Molecular diagnostics recovery boosted by non-respiratory test demand.Danaher Corporation’s (DHR) Diagnostics segment continues to contribute steadily to its overall performance. The segment’s core revenues increased 2% on a year-over-year basis in the second quarter of 2025.Solid momentum in the clinical diagnostics businesses, led by growth in the Beckman Colter Di ...